Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Beats Estimates By $0.93 EPS

Keros Therapeutics (NASDAQ:KROS) posted its earnings results on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93, Zacks reports. The company had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.63%. Keros Therapeutics’s quarterly revenue was up 3585.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.41) EPS.

Keros Therapeutics Stock Performance

Shares of KROS traded down $0.16 during trading hours on Friday, hitting $16.01. The stock had a trading volume of 663,650 shares, compared to its average volume of 914,586. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm has a 50-day moving average price of $15.48 and a 200 day moving average price of $14.61. The firm has a market capitalization of $487.86 million, a price-to-earnings ratio of 10.41, a PEG ratio of 2.02 and a beta of 1.12.

Insider Transactions at Keros Therapeutics

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The SEC filing for this sale provides additional information. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. PDT Partners LLC increased its position in Keros Therapeutics by 20.6% during the 2nd quarter. PDT Partners LLC now owns 332,815 shares of the company’s stock worth $4,443,000 after purchasing an additional 56,755 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Keros Therapeutics during the 2nd quarter worth approximately $4,251,000. Caption Management LLC boosted its position in Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after purchasing an additional 291,997 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after buying an additional 988 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Keros Therapeutics by 30.4% during the second quarter. Invesco Ltd. now owns 43,395 shares of the company’s stock worth $579,000 after purchasing an additional 10,129 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on KROS. Weiss Ratings reissued a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company assumed coverage on shares of Keros Therapeutics in a report on Monday, October 20th. They issued an “overweight” rating and a $26.00 price objective for the company. HC Wainwright decreased their price target on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Wedbush boosted their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and an average price target of $30.11.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.